Prab at 00:23, 17 March 2025

2025-03-17T00:23:27Z

← Older revision		Revision as of 00:23, 17 March 2025
Line 25:		Line 25:
	[[Category:Neuroscience]]		[[Category:Neuroscience]]
	{{Pharma-stub}}		{{Pharma-stub}}
	~~{{No image}}~~
	<gallery>		<gallery>
	File:LM22A-4 structure.svg\|LM22A-4		File:LM22A-4 structure.svg\|LM22A-4
	</gallery>		</gallery>

Prab: CSV import

2025-02-20T01:22:46Z

CSV import

← Older revision		Revision as of 01:22, 20 February 2025
Line 26:		Line 26:
	{{Pharma-stub}}		{{Pharma-stub}}
	{{No image}}		{{No image}}
			<gallery>
			File:LM22A-4 structure.svg\|LM22A-4
			</gallery>

Prab: CSV import

2025-02-11T03:02:19Z

CSV import

← Older revision		Revision as of 03:02, 11 February 2025
Line 25:		Line 25:
	[[Category:Neuroscience]]		[[Category:Neuroscience]]
	{{Pharma-stub}}		{{Pharma-stub}}
			{{No image}}

Prab: CSV import

2024-02-28T20:04:03Z

CSV import

New page

'''LM22A-4''' is a small molecule, developed by [[Ligand Pharmaceuticals]], that acts as a [[Brain-derived neurotrophic factor|BDNF]] mimetic. It is designed to bind to and activate the [[TrkB receptor]], which is the primary receptor for BDNF in the brain. This activation is believed to promote the survival and growth of neurons, and to enhance synaptic plasticity, which is the ability of synapses to strengthen or weaken over time in response to increases or decreases in their activity.

== Mechanism of Action ==

LM22A-4 mimics the action of BDNF by binding to the TrkB receptor and activating it. This activation triggers a series of intracellular signaling cascades, including the [[Mitogen-activated protein kinase|MAPK]] pathway, the [[Phosphoinositide 3-kinase|PI3K]] pathway, and the [[Phospholipase C|PLC]] pathway. These pathways are involved in various cellular processes, including cell survival, growth, and differentiation, as well as synaptic plasticity.

== Therapeutic Potential ==

Due to its ability to promote neuronal survival and growth, and to enhance synaptic plasticity, LM22A-4 has potential therapeutic applications in a variety of neurological and psychiatric disorders. These include [[Alzheimer's disease]], [[Parkinson's disease]], [[Huntington's disease]], [[Amyotrophic lateral sclerosis|ALS]], [[Depression (mood)|depression]], and [[Schizophrenia]]. Preclinical studies have shown that LM22A-4 can improve cognitive function, reduce neuronal death, and alleviate depressive-like behaviors in animal models of these disorders.

== Clinical Development ==

As of 2021, LM22A-4 is in the preclinical stage of development. It has been tested in various in vitro and in vivo models, and has shown promising results. However, it has not yet been tested in humans, and its safety and efficacy in humans remain to be established.

== See Also ==

* [[Brain-derived neurotrophic factor]]
* [[TrkB receptor]]
* [[Neurotrophin]]
* [[Neurodegenerative disease]]
* [[Neuroplasticity]]

[[Category:Experimental drugs]]
[[Category:Neurotrophin receptor agonists]]
[[Category:Neuroscience]]
{{Pharma-stub}}

LM22A-4 - Revision history

Prab at 00:23, 17 March 2025

Prab: CSV import

Prab: CSV import

Prab: CSV import